Pitolisant

• Tiprolisant ( USAN )
• BF 2649
• 1 - ( 3 - (3 - (4- chlorophenyl ) propoxy ) propyl ) piperidine (IUPAC)

White solid

Antihistamine

Histamine H3 - receptor antagonist

Soluble in water

Template: Infobox chemical / molecular formula search available

Pitolisant ( Tiprolisant, BF 2649 ) is a clinical- trial drug from the group of H3 antihistamines. Pitolisant was developed by the French pharmaceutical company Bioprojet. For a possible application for the treatment of excessive daytime sleepiness (EDS ) associated with narcolepsy Pitolisant the status of an orphan medicinal product has been granted. Also, other potential applications of this drug, such as the improvement of cognitive ability in schizophrenia patients and the treatment of excessive daytime sleepiness in the sleep apnea syndrome and Parkinson 's disease, are currently in Phase II and Phase III clinical research.

Pharmacological properties

Pitolisant mediates its activity as antihistamine H3 via a inverse agonism at the histamine H3 receptor. His affinity for this receptor is in the low nanomolar range.